Arrowstreet Capital’s Sage Therapeutics SAGE Stock Holding History

Arrowstreet Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-85,073	Closed	-$4M	–	1401
2023 Q2	$4M	Buy	+85,073	New	+$4.23M	﹤0.01%	671

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's SAGE Position: Q3 2023 in Review

Arrowstreet Capital sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 85,073 shares — an estimated $4M sold.

Arrowstreet Capital first reported a position in SAGE in Q2 2023 and held it in 1 quarter. The position peaked at $4M in Q2 2023. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

Arrowstreet Capital reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
Arrowstreet Capital sold 85,073 Sage Therapeutics shares in Q3 2023, an estimated $4M.
Arrowstreet Capital first reported a position in Sage Therapeutics in Q2 2023 and held it in 1 quarter.
Arrowstreet Capital's Sage Therapeutics position peaked at $4M in Q2 2023.
194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Arrowstreet Capital's 13F filing for Q3 2023, filed 14 Nov 2023.